CME Activities

CLICK ON STATES TO SEE GRAND ROUNDS ACTIVITIES

 

Online Activities

 

Jun
30
Tue
A Virtual Reality View: Incorporating GLP-1 Receptor Agonists into Clinical Practice: Personalizing Therapy to Improve Glycemic and Extra-glycemic Outcomes
Jun 30 2020 @ 12:00 am – Jun 30 2021 @ 2:09 am

A Virtual Reality View: Incorporating GLP-1 Receptor Agonists into Clinical Practice: Personalizing Therapy to Improve Glycemic and Extra-glycemic Outcomes

View Activity

FACULTY

Richard E. Pratley, MD
Senior Investigator and Diabetes Program Lead, Translational Research Institute
Medical Director, AdventHealth Diabetes Institute
Orlando, FL

Guillermo E. Umpierrez, MD, CDE
Professor of Medicine
Emory University
Section Head, Diabetes & Endocrinology
Grady Health System
Atlanta, Georgia

PROGRAM OVERVIEW

This case-based activity will cover the diagnosis, treatment, and management of patients with type 2 diabetes.

TARGET AUDIENCE

This educational activity is intended for endocrinologists, primary care physicians, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals who diagnose, treat, and manage patients with type 2 diabetes.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

  • Discuss the physiologic role of GLP-1 and the mechanism of action of GLP-1 receptor agonists
  • Personalize the selection of GLP-1 receptor agonists by considering patient-specific factors, such as comorbidities, age, route and frequency of administration, and others
  • Evaluate clinical trial data on the impact of GLP-1 receptor agonists on glycemic control and cardiovascular and renal outcomes
  • Develop tailored antihyperglycemic regimens for patients with type 2 diabetes based on guideline recommendations, individualized glycemic goals, and patient-specific factors

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this web-based activity for a maximum of 2.0 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the diagnosis, treatment, and management of patients with type 2 diabetes. CNE Credits: 2.0 ANCC Contact Hours.

CNE ACCREDITATION STATEMENT:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 2.0 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

FACULTY
Richard E. Pratley, MD receives consulting fees from AstraZeneca, GlaxoSmithKline, Glytec LLC, Janssen, Ligand Pharmaceuticals, Lilly, Merck, Novo Nordisk, and Sanofi and speaker fees from AstraZeneca and Novo Nordisk. All payments for Dr. Richard Pratley’s services were made directly to AdventHealth, a nonprofit organization.

He has contracted research for Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Lilly, Merck, Novo Nordisk and Sanofi. All grant fund payments were made directly to AdventHealth, a nonprofit organization.

Guillermo E. Umpierrez, MD, CDE has contracted research with Dexcom Inc. and Sanofi Inc.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group has nothing to disclose.
Diana Tommasi, Medical Director of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: June 30, 2020

EXPIRATION DATE: June 30, 2021

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

View Activity

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Sep
17
Thu
The Virtual Reality Room: Individualizing Treatment with GLP-1 Receptor Agonists: Targeting the Pathophysiology of Type 2 Diabetes
Sep 17 2020 @ 3:47 pm – Sep 17 2021 @ 4:47 pm

FACULTY

Robert Busch, MD
Endocrinology, Diabetes, & Metabolism
AMC Community Division
The Endocrine Group
Albany, New York

PROGRAM OVERVIEW

This activity will cover the diagnosis, treatment, and management of patients with type 2 diabetes.

TARGET AUDIENCE

This educational activity is intended for endocrinologists, primary care physicians, physician assistants, nurse practitioners, pharmacists, and other healthcare professionals who diagnose, treat, and manage patients with type 2 diabetes.

LEARNING OBJECTIVES

  • Utilize knowledge of the underlying pathophysiologic defects in type 2 diabetes to select treatment regimens that improve patient outcomes by targeting multiple core defects
  • Review the mechanism of action of GLP-1 receptor agonists and evaluate the impact of these agents on HbA1C, postprandial glucose, and fasting plasma glucose levels
  • Apply current treatment guidelines and evidence supporting early therapy initiation and treatment intensification into management plans for patients with type 2 diabetes
  • Develop patient-centered approaches that optimize the use of GLP-1 receptor agonists and minimize cardiovascular risk in patients with type 2 diabetes

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the diagnosis, treatment, and management of patients with type 2 diabetes. CNE Credits: 1.0 ANCC Contact Hour(s).

CNE Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Robert Busch, MD reports that he has served on speakers bureaus for Amgen, Astra-Zeneca, Boehringer Ingelheim, Janssen, Novo Nordisk, Lilly, and Sanofi. In addition, he has received research grants from Astra-Zeneca, Gilead, Kowa Pharma, Novo Nordisk, Lilly, and Sanofi.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group has nothing to disclose.
Diana Tommasi, Medical Director of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures;
  2. Participate in the activity; and
  3. Complete pre-and-post surveys and evaluation.

Complete pre-and-post surveys and evaluation.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com

 

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

Institution-based grand rounds meetings held throughout the United States. Each presentation is held for 1 hour. These meetings do not have open registration. Please click on the above links for information about other live or online CME events.

 

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. These CME activities are planned and produced in accordance with the ACCME Essentials.